PSYCARIA - EMOTION DETECTOR FOR A PSYCHIATRIST

Every person will experience stress around the world, some healthy, called EUSTRESS and some unpleasant, named DISTRESS. Good pressure and stress promote success. Stress damages people's lives and health and causes various diseases. On the other hand, psychiatrists have a hard time treating their patients owing to a lack of time. They need innovative and intelligent equipment to treat their patients. We prepared a device that can detect a person's POSITIVE and NEGATIVE emotions through a smartwatch and a gadget that can sense body temperature, respiration, and heart rate. After witnessing these parameters, it can store the results on a website depending on the patient's condition. For example, the psychiatrist observed one patient for at least seven days regarding the days' results stored on a website. After seven days, the report is generated. The goal of psychiatrists in keeping their patients for seven days is to assess their emotional health and determine if they need to adjust their treatment. This system detects eight positive and negative emotions through heartbeat, respiratory, and body temperature sensors. These sensors are incorporated by utilizing machine learning. Web-based apps interpret sensor readings. Psychiatrists will analyze and report the website's results

Post-Transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Characteristics, Management and Outcome from a Single-Centre Experience with >1000 Liver Transplantations

BACKGROUND: The literature regarding post-transplant lymphoproliferative disorder (PTLD) in liver transplant recipients (LTRs) is limited

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience

Introduction. Hepatitis C (HCV) continues to be the leading indication for liver transplantation (LT). Sustained virological response (SVR) rates to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for recurrent HCV in Genotype 1 (G1) LT recipients have been disappointing (30-40%). Experience with triple therapy using protease inhibitors (PI) boceprevir (BOC), telaprevir (TVR) in these patients has been limited.Material and methods. This national multicenter retrospective study included 76 patients (64 male, mean age 57 ± 6 years), treated for G1 HCV recurrence with either BOC (n = 41) or TVR (n = 35), who were non-responders or relapsers (n = 54), treatment naïve (n = 22) or had fibrosing cholestatic HCV (n = 3). 53 patients were on cyclosporine, 22 on tacrolimus and one patient on prednisone alone.Results. On treatment virologic response was observed in 84% (64/76), 83% in BOC and 85% in TVR group. A higher week 4 response after starting triple therapy (RVR) was noted in TVR group 25/35 (81%) as compared to BOC group 26/41 (63%); p value = 0.02. The end of treatment response was 78% and 75% in BOC and TVR group, respectively. SVR 12 weeks after treatment discontinuation was observed in 59.5% (22/37); 58.3% in the BOC group and 61.5% in TVR group. Treatment was discontinued early in 23 patients (serious adverse effects n = 19, treatment failure n = 4). Infections occurred in 5 patients with 2 deaths (all in BOC). Anemia was the most common side effect (n = 55, 72%) requiring erythropoietin and RBV dose reduction. In the BOC group, cyclosporine dose reduction was 2.2 ± 1.0 fold and 8.6 ± 2.4 fold with tacrolimus. In TVR group, dose reduction was 3.0 ± 1.4 with cyclosporine and 12 ± 5.7 fold with tacrolimus. Conclusions. PI-based triple therapy appears more effective in producing HCV-RNA clearance than dual therapy. Tolerability is a serious issue and drug-drug interactions are manageable with close monitoring